protein degrader

Protein degraders enter the clinic

Read more in our April issue

  • Deborah Chirnomas
  • Keith R. Hornberger
  • Craig M. Crews
Review Article


  • viral particles

    Read all the COVID-19-related contents published in our journal, which will be freely available during the pandemic

  • five diverse women

    This regularly updated collection of articles published in the Nature Reviews journals provides in-depth discussions of recent research and medical advances in fields covering women’s health in the broadest sense.


    • Globally, gastric cancer is a common and highly fatal cancer with two anatomical subtypes, non-cardia and cardia gastric cancer. Helicobacter pylori causes almost 90% of distal gastric cancers worldwide. The authors of this Review summarize the current epidemiology of gastric cancer and the evidence and implications of primary and secondary prevention efforts.

      • Aaron P. Thrift
      • Theresa Nguyen Wenker
      • Hashem B. El-Serag
      Review Article
    • Advances in surgical technique and chemotherapy regimens have improved the survival outcomes of patients with pancreatic cancer, although these remain dismal relative to most other solid tumours. Attempts to further improve outcomes have led to increasing research interest in neoadjuvant therapy, which is beginning to improve the outcomes of certain subgroups of patients. In this Review, the authors provide an overview of the various neoadjuvant therapy approaches for patients with pancreatic cancer, including discussions of several promising future research directions

      • Christoph Springfeld
      • Cristina R. Ferrone
      • John Neoptolemos
      Review Article
    • Allele-specific inhibitors of KRASG12C are approved in non-small-cell lung cancer. Herein, we discuss recent results from the phase I/II KRYSTAL-1 trial of adagrasib alone and in combination with cetuximab in patients with KRASG12C-mutant metastatic colorectal cancer. The combination had promising efficacy and, if confirmed in later-phase trials, concomitant inhibition of EGFR and KRASG12C will present a new paradigm in precision oncology.

      • Federica Di Nicolantonio
      • Alberto Bardelli
      News & Views
    • Bladder cancer is among the ten most common cancers worldwide and therefore constitutes a substantial health-care burden. This Review summarizes the global trends in bladder cancer incidence and mortality, and describes the main risk factors associated with bladder cancer occurrence and outcomes. The implications, challenges and opportunities of these epidemiological trends for public health and clinical practice are also discussed.

      • Lisa M. C. van Hoogstraten
      • Alina Vrieling
      • Lambertus A. Kiemeney
      Review Article
    • Genomics-based precision medicine has improved the outcomes of patients with certain types of cancers, although most do not derive benefit. Here, the authors describe the development of functional patient-specific assays, including those based on organoids, spheroids and explants, and how clinical implementation of these models might extend the benefits of precision medicine to a much broader range of patients.

      • Allard W. J. van Renterghem
      • Joris van de Haar
      • Emile E. Voest
      Review Article

Nature Careers